Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays
Synthace, the leader in software and services for assay development, today announced a collaboration with Charles River Laboratories International, Inc. (Charles River), a leading global drug discovery, development, testing, and manufacturing…
UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) - Here's Why
Royalty Pharma Plc (NASDAQ: RPRX) is one of the best healthcare stocks under $50 to invest in. On January 30, Royalty Pharma Plc (NASDAQ:RPRX) was upgraded to Buy from Neutral by UBS, with the firm raising the price target on the stock to $49 from…
'We fought monopoly, not science': Pharma leaders debate India's future
4 min read Mumbai Make us preferred source on Google “We fought against monopoly, not science,” said Dr Yusuf Hamied of Cipla, recalling how Indian drugmakers campaigned for the Patents Act of 1972. He described telling then Prime…
Indiana wins $6.25M settlement from pharma firms over EpiPen prices
INDIANAPOLIS (WISH) — Indiana will receive $6.25 million as part of a settlement with pharmaceutical companies following allegations they conspired to inflate EpiPen prices by more than 600%. Attorney General Todd Rokita announced the…
Pharma leaders seek regulatory reform, faster trials to spur innovation
Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book Made in India — The Story of Desh Bandhu Gupta, Lupin and Indian Pharma, industry stalwarts including Dilip Shanghvi, managing director of Sun…
JM Financial flags growth concerns in Mankind Pharma; initiates with Reduce
Domestic brokerage JM Financial has initiated coverage on pharmaceutical company Mankind Pharma with a 'Reduce' rating, citing moderating growth in its core India business, high exposure to slow-growing and mature therapies, and limited scope for a…
Stocks to Watch today: Aurobindo Pharma, BSE, Eternal, Pfizer, Trident
Stocks to watch today, Tuesday, February 10, 2026: GIFT Nifty indicates that Indian markets may extend gains on Tuesday. The futures were quoting at 25,988, up 79.50 points or 0.31 per cent as of 7:39 AM. Most markets in Asia-Pacific rose in early…
Lupin settles dispute with Astellas Pharma, keeps Mirabegron sales in US
Under the agreement, Lupin and its US unit will pay Astellas $90 million, including a $75 million upfront payment and per-unit licensing fees on Mirabegron sales through September 2027 | Photo: X@LupinGlobal 1 min read Last Updated: Feb 10 2026 |…
Aurobindo Pharma board considers merger of subsidiaries
Last Updated: Feb 09 2026 | 7:51 PM IST Approves filing of scheme of merger of Auro Vaccines with Curateq Biologics The board of Aurobindo Pharma at its meeting held on 09 February 2026 has approved a proposal to file a scheme of amalgamation for…
Board of Aurobindo Pharma approves PPA with Garuda Renewables
Last Updated: Feb 09 2026 | 7:51 PM IST Also approves investment of Rs 66 cr in Garuda Renewables The board of Aurobindo Pharma at its meeting held on 09 February 2026 has approved to enter into a power purchase agreement with Garuda Renewables, to…
CM urged to lobby for setting up national pharma institute in capital
The Trivandrum Chamber of Commerce and Industry has requested Chief Minister Pinarayi Vijayan to take steps to establish the National Institute of Pharmaceutical Education and Research (NIPER) in Thiruvananthapuram. The Chamber noted that the State…
Aurobindo Pharma sinks 8%, stock hits over 3-month low post Q3 results
Share price of Aurobindo Pharma hit an over three-month low at ₹1,110.55, falling 8 per cent on the BSE in Tuesday's intra-day trade after the company announced December 2025 quarter (Q3FY26) results on Monday after market hours. The stock…
Aurobindo Pharma Q3 net up 7.6% to ₹910 cr. on higher Europe, ARV revenue
Generic drugmaker Aurobindo Pharma reported December quarter consolidated net profit increased 7.6% to ₹910 crore compared to the ₹846 crore a year earlier. The profit came on a more than 8% increase in revenue from operations to…
Aurobindo Pharma Q3FY26 results: Net profit rises 8% to ₹910 crore
Aurobindo Pharma on Monday said its consolidated net profit increased 8 per cent year-on-year to ₹910 crore for the December quarter, led by robust sales in Europe and the US. The Hyderabad-based drug major reported a net profit of…
Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue selling the product in the…
Receive a Daily briefing on Pharma Industry News
Get Started